Company profile: Mymetics
1.1 - Company Overview
Company description
- Provider of virosome-based vaccine R&D and immunotherapies, focused on next-generation preventative vaccines for infectious diseases. Pipeline includes HIV-1/AIDS, intranasal influenza, malaria, herpes simplex virus and RSV, plus candidates for Covid-19 and COP allergy immunotherapy, and research collaborations in cancer immunotherapy. Swiss-based with a research lab in the Netherlands.
Products and services
- HIV Vaccine Candidate: A mucosal-targeted, virosome-based vaccine candidate inducing mucosal antibodies to prevent HIV-1 transmission, tested in preclinical studies for preventative efficacy
- Malaria Vaccine Candidate: A transmission-blocking, virosome-based vaccine engineered to target Plasmodium falciparum, designed to block parasite transmission and enhance immune response without causing disease
- Virosome-based Vaccines: A virosome-based platform engineering virus-like particle assemblies that enhance immune response without causing disease, enabling next-generation preventative vaccines for HIV-1/AIDS, intra-nasal Influenza, Malaria, Herpes Simplex Virus, and RSV
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Mymetics
Claritas Pharmaceuticals
HQ: United States
Website
- Description: Provider of next-generation cannabinoid therapeutics, pioneering their development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Claritas Pharmaceuticals company profile →
Aptorum
HQ: United Kingdom
Website
- Description: Provider of pharmaceutical discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, with a focus on infectious diseases and cancers, including orphan oncology indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aptorum company profile →
Biotest Pharmaceuticals
HQ: United States
Website
- Description: Provider of pharmaceutical and biotherapeutic products utilized in immunology, with innovation in haematology, clinical immunology and intensive care medicine, incorporating innovative technologies and a sharp focus on safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biotest Pharmaceuticals company profile →
BioMed Diagnostics
HQ: United States
Website
- Description: Provider of highly selective pre-plated prepared media culture devices that combine inoculation, culture, transport, and result analysis to reduce lab labor and costs. Solutions span clinical, veterinary point-of-care, and industrial microbiology for environmental monitoring and compliance, including InPouch, InTray, and PCR-compatible Transit Tube.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioMed Diagnostics company profile →
Ibis Biosciences
HQ: United States
Website
- Description: Provider of products for the identification and characterization of infectious agents, including the Ibis T5000 Biosensor System, a hardware platform that identifies biological organisms such as bacteria, viruses, fungi and protozoa and provides information on drug resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ibis Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Mymetics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Mymetics
2.2 - Growth funds investing in similar companies to Mymetics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Mymetics
4.2 - Public trading comparable groups for Mymetics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →